Virtual Incision — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Virtual Incision is a private medical device company developing the MIRA Surgical System, a novel, portable robotic-assisted surgery (RAS) platform. Founded in 2006 and based in Lincoln, Nebraska, the company aims to democratize robotic surgery by overcoming the cost, size, and complexity barriers of traditional 'mainframe' systems. Its tray-to-table design targets increased surgical throughput and broader adoption in hospitals, with initial clinical applications in colorectal and gynecological procedures. The company is in the commercial launch phase, having received FDA clearance for specific indications.

SurgeryColorectalGynecology

Technology Platform

Miniaturized Robotic-Assisted Surgery (miniRAS) platform featuring the MIRA Surgical System, a portable, single-port, self-contained robotic device designed for tray-to-table use in standard operating rooms.

Opportunities

The primary opportunity is to capture a large, underserved market of mid-tier hospitals and ASCs that cannot afford traditional robotic systems, by offering a lower-cost, portable alternative.

The shift towards value-based care and outpatient surgery further supports the adoption of efficient, minimally invasive technologies like MIRA.

Risk Factors

Key risks include commercial execution challenges in a crowded market, the need to generate extensive clinical data to drive adoption, potential limitations of the single-port approach for complex cases, and competitive responses from large, established players in surgical robotics.

Competitive Landscape

Virtual Incision competes in the robotic-assisted surgery market, which is dominated by Intuitive Surgical (da Vinci). Its primary differentiation is miniaturization and portability, targeting a different customer segment. It also faces competition from other new entrants and laparoscopic instrument companies. Its strategy is to complement, not directly replace, mainframe systems.

More companies in Digital Health & Biotech SaaS →More companies in United States →